Kathryn C. Arbour, MD, is a thoracic medical oncologist at Memorial Sloan Kettering Cancer Center in New York.
Daraxonrasib is being evaluated as an oral multiselective inhibitor for individuals with previously treated advanced lung cancer carrying specific genetic mutations.
Dr. Kathryn C. Arbour presents preliminary findings from a Phase 1 study showing that zoldonrasib, a selective RAS(ON) G12D inhibitor, demonstrates encouraging antitumor activity and a manageable safety profile in patients with previously treated KRAS G12D–mutant non–small cell lung cancer.
Dr Arbour discusses the mechanisms of action of zoldonrasib and daraxonrasib and shares early data with these agents in RAS-mutant NSCLC.
Kathryn C. Arbour, MD, highlights the safety and early efficacy of zoldonrasib in patients with non–small cell lung cancer harboring KRAS G12D mutations.
Isabel Preeshagul, DO, MBS, and colleagues share updates from across the lung cancer space as discussed in a recent State of the Science Summit.
Kathryn C. Arbour, MD, discusses preliminary safety and efficacy data with the RAS inhibitor RMC-6236 in patients with KRAS-mutated non–small cell lung cancer.
April 28th 2025
